GSK plc GLAXF OTC · Healthcare · United Kingdom
$23.40 -4.29% -$1.05
Summary
65 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- Out of every 100 GBP of revenue, 13 GBP is left as net profit.
What to watch
- Earnings per share fell by 28% a year over the last 3 years.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 16.6 GBP for 1 GBP of yearly profit. Over the last five years it was 13.2 GBP on average.
Valuation in detailIs it growing?
SlowlyRevenue (GBP)
Diluted EPS (GBP)
- Analyst estimate
Revenue fell by 0.9% a year over 5 years. Over the last 3 years it grew by 3.7% a year. For the next fiscal year analysts expect revenue to grow by 3.9%.
Growth in detailDoes it make money?
Very wellWhere 100 GBP of revenue goes
- Cost of sales 26 GBP
- Research and development 23 GBP
- Sales and administration 32 GBP
- Taxes and other 5.8 GBP
- Net profit 13 GBP
Net profit, industry median (Drug Manufacturers - General) 14 GBP
Out of every 100 GBP of revenue, 13 GBP is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 3.5 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, stretched- Yield
- 3.95%
- Paid out of profit
- 66%
- Raised in a row
- 2 years
You receive $0.92 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- International 55%
- Europe 45%
International brings in 55% of revenue.
Segments in detail